About Ergomed

About Ergomed

Founded in 1997, Ergomed plc is dedicated to the provision of specialized services to the pharmaceutical industry and the development of new drugs.

With a global footprint covering 100+ countries, we have the reach to deliver solutions for even the toughest clinical development and trial management challenges.

Ergomed has provided clinical development, trial management, and pharmacovigilance services for 300+ clients, from top 10 pharmaceutical and generics organizations to small and mid-sized drug development companies.

Our Offices

Filter by Country
- Europe and Mediterranean
  - United Kingdom
  - Netherlands
  - Germany
  - Poland
  - Russia
  - Czech Rep.
  - Croatia
  - Serbia
  - Bosnia and Herz.
  - Ireland
  - France
  - Switzerland
  - Italy
  - Spain
  - Portugal
  - Romania
  - Bulgaria
  - Ukraine
- Americas
  - United States
  - Canada
- Asia
  - Japan
  - India

Reset

Our History

1997
Ergomed begins
Clinical investigator Dr. Miroslav Reljanović founds Ergomed in Zagreb, Croatia.
2006
First co-development deal
Dr. Reljanovic successfully introduces an innovative co-development business model to support clinical programs across Europe.
2008
PrimeVigilance launches
Well-known international drug safety expert, Elliot Brown, and Dr. Reljanović form PrimeVigilance, which aims to be a leading specialist in pharmacovigilance services.
2014
Ergomed IPO
Ergomed is successfully added to the AIM market of the London Stock Exchange and trades under the symbol ERGO.
2015
Aquisiton of Sound Opinion
Ergomed acquires Sound Opinion, a medical information service company, to bolster the PrimeVigilance offering.
2016
Acquisition of Haemostatix
Ergomed acquires Nottingham-based Haemostatix to access its proprietary technology and pipeline products PeproStat™ and ReadyFlow™.
2016
Acquisition of O+P, GASD
German-based CRO company, O+P, and GASD, a biostatistics company, is acquired to bolster Ergomed’s full-service offering.
2016
Acquisition of PharmInvent
Ergomed acquires leading pharmacovigilance and regulatory services business, PharmInvent.
2017
Acquisition of PSR
Ergomed acquires PSR Group BV, a specialist orphan drug CRO, to further enhance its expertise in rare diseases.
2020
Acquisition of Ashfield PV
Ashfield Pharmacovigilance, a US-based specialist pharmacovigilance services provider, is acquired to increase our support for US clients.
2020
Acquisition of MedSource
Ergomed acquires MedSource, an award-winning, oncology-focused US-based CRO to further grow our footprint in the US.
2022
Acquisition of ADAMAS
Ergomed acquires ADAMAS, a leading global regulatory compliance provider.

Explore more about Ergomed

Download brochure

Our Companies

Ergomed CRO

Our heritage working in co-development arena means that we understand all the pain points and needs better than others. More than 40% of our workforce hold a PhD, MD or advanced degree qualification.

Visit Ergomed CRO

PrimeVigilance

PrimeVigilance covers the entire product life cycle, assisting clients with the effective management of their drug safety information, and offering expert consulting services from former regulators and opinion leaders.

Visit PrimeVigilance

Our Environmental, Social and Governance Policy